Welcome to our dedicated page for Can-Fite BioPharma news (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite BioPharma stock.
Can-Fite BioPharma Ltd. reports developments for a clinical-stage biotechnology pipeline of proprietary small-molecule drugs targeting the A3 adenosine receptor (A3AR). Recurring news covers Namodenoson and Piclidenoson across oncology, inflammatory disease, liver disorders, metabolic disease, obesity-related uses, and companion-animal osteoarthritis through its veterinary commercialization relationship.
Company updates also include clinical and regulatory disclosures, patent allowances in multiple jurisdictions, operating and financial results, material agreements, capital-structure actions, and governance matters tied to its American Depositary Shares and ordinary-share voting processes.
Can-Fite BioPharma Ltd. (NYSE American: CANF) reported its financial results for Q1 2022, with revenues of $0.20 million, up 38.5% from $0.15 million in Q1 2021. The company holds $16.5 million in cash and equivalents. R&D expenses rose 39.8% to $1.82 million due to ongoing clinical trials for psoriasis and NASH treatments. The net loss increased to $2.43 million from $1.87 million year-on-year. Upcoming milestones include Phase III psoriasis study results expected in Q2 2022 and ongoing Phase IIb and III studies for NASH and liver cancer.
Can-Fite BioPharma Ltd. (NYSE American: CANF) has received a patent for its A3 Adenosine Receptor ligand aimed at treating ectopic fat accumulation, particularly in non-alcoholic steatohepatitis (NASH) and fatty liver disease. The patent is recognized in about 40 countries, including Japan and the EU. The market for NASH treatment is expected to reach $35 billion by 2025. Can-Fite is currently conducting a Phase IIb clinical trial for its drug candidate Namodenoson, which previously met key endpoints in Phase IIa trials, showing safety and efficacy in reducing liver fat.
Can-Fite BioPharma (NYSE American: CANF) announced a Phase II study where Namodenoson, an oral drug targeting liver cancer, cleared all lesions in an advanced patient. The pivotal Phase III trial has received FDA and EMA approval and is now open to recruit around 450 hepatocellular carcinoma patients. The drug selectively binds to the A3 adenosine receptor, prevalent in cancer cells. CEO Dr. Pnina Fishman is set to present at the Adenosine Pathway Targeted Cancer Immunotherapy Summit in Boston on May 12, 2022, highlighting the drug's promising results.
Can-Fite BioPharma (NYSE American: CANF) is advancing a topical treatment for psoriasis using its Phase III oral drug candidate, Piclidenoson. Recent preclinical studies show significant efficacy in managing psoriasis symptoms. The global psoriasis drug market, valued at $11.37 billion, is projected to grow at a CAGR of 6.5%. Can-Fite expects to release topline results for its Phase III trial in Q2 2022, with positive interim data supporting the development of its topical formulation as a complement to the oral treatment.
Can-Fite BioPharma Ltd (NYSE American: CANF) announced that CEO Dr. Pnina Fishman will present at the 3rd Annual Dermatology Drug Development Summit on April 6, 2022, showcasing the lead drug candidate Piclidenoson for psoriasis treatment. Enrollment in the Phase III Comfort™ study is complete with 400 patients across 30 sites in Europe, Israel, and Canada, with topline data expected in Q2 2022. The company has received approximately $20 million from licensing agreements, enhancing its market reach in various countries.
Can-Fite BioPharma (NYSE: CANF) announced its financial results for the year ended December 31, 2021, reporting revenues of $0.85 million, up from $0.76 million in 2020. The company had a cash balance of $18.9 million at year-end. Key developments include a significant $42.7 million out-licensing deal with Ewopharma and positive Phase II results for Namodenoson in liver cancer. A Phase III study for liver cancer is set to start in H1 2022, and topline data for psoriasis is expected in Q2 2022.
Can-Fite BioPharma Ltd (NYSE: CANF) announced a Notice of Allowance from the U.S. Patent and Trademark Office for its method to treat advanced liver fibrosis with Namodenoson. This expansion targets various liver conditions including NASH and liver cancer, tapping into a market projected to exceed $20 billion by 2020.
The company is currently enrolling patients for a Phase IIb trial for NASH and plans to begin a Phase III trial for advanced liver cancer. Namodenoson boasts a strong safety profile and significant commercial potential.
Can-Fite BioPharma Ltd (NYSE American: CANF) announced its CEO, Dr. Pnina Fishman, will present research at the CannX Medical Cannabis Conference on March 14-15, 2022, focusing on cannabinoids' role in liver cancer treatment.
Key findings indicate that CBD-rich T3/C15 can inhibit hepatocellular carcinoma growth at low concentrations by activating the A3 adenosine receptor. Can-Fite is exploring collaboration opportunities within the cannabis sector for potential licensing.
The abstract will be published in the Medical Cannabis and Cannabinoids journal.
Can-Fite BioPharma (NYSE American: CANF) announced an unexpected delay in releasing top-line data from its Phase III Comfort™ study of Piclidenoson for treating plaque psoriasis, now expected in Q2 2022. The study involves over 400 patients across Europe, Israel, and Canada. Piclidenoson aims to target key cytokines involved in skin lesions. The psoriasis market is projected to reach $11.3 billion by 2025, with potential milestone payments from out-licensing agreements. The company remains optimistic about the drug's effectiveness with minimal side effects.
Can-Fite BioPharma (NYSE American: CANF) announced the enrollment of the first patient in a Phase IIb study for its drug candidate Namodenoson, targeting non-alcoholic steatohepatitis (NASH). This multicenter, randomized trial aims to assess Namodenoson's efficacy compared to placebo in 140 subjects over 36 weeks. The NASH market is projected to reach $35-$40 billion by 2025, highlighting the growth potential. Previous Phase IIa results indicated promising outcomes related to liver fibrosis and inflammation.